

Zhanjun Hou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/302035/publications.pdf>

Version: 2024-02-01

52
papers

1,815
citations

257357

24
h-index

276775

41
g-index

53
all docs

53
docs citations

53
times ranked

1476
citing authors

#	ARTICLE	IF	CITATIONS
1	The evolving biology of the proton-coupled folate transporter: New insights into regulation, structure, and mechanism. <i>FASEB Journal</i> , 2022, 36, e22164.	0.2	9
2	Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 191.	1.7	12
3	Pattern Analysis of Organellar Maps for Interpretation of Proteomic Data. <i>Proteomes</i> , 2022, 10, 18.	1.7	9
4	Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
5	Folate transporter dynamics and therapy with classic and tumor-targeted antifolates. <i>Scientific Reports</i> , 2021, 11, 6389.	1.6	15
6	Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 37, 116093.	1.4	6
7	A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis. <i>Blood</i> , 2021, 138, 2238-2238.	0.6	0
8	Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2245-2255.	1.9	38
9	Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-d]pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism. <i>Molecular Pharmacology</i> , 2020, 97, 9-22.	1.0	21
10	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115544.	1.4	10
11	Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1787-1799.	1.9	38
12	Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor $\hat{\pm}$ and inhibition of de novo purine nucleotide biosynthesis. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115125.	1.4	1
13	Regulation of differential proton-coupled folate transporter gene expression in human tumors: transactivation by KLF15 with NRF-1 and the role of Sp1. <i>Biochemical Journal</i> , 2019, 476, 1247-1266.	1.7	3
14	Development and validation of chemical features-based proton-coupled folate transporter/activity and reduced folate carrier/activity models (pharmacophores). <i>Journal of Molecular Graphics and Modelling</i> , 2018, 81, 125-133.	1.3	0
15	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3-d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor $\hat{\pm}$ and the Proton-Coupled Folate Transporter and Inhibition of <i>De Novo</i> Purine Nucleotide Biosynthesis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2027-2040.	2.9	11
16	Fluorine-Substituted Pyrrolo[2,3-d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor $\hat{\pm}$ and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4228-4248.	2.9	21
17	The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 1-15.	1.1	36
18	Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor $\hat{\pm}$ and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 819-830.	1.9	40

#	ARTICLE	IF	CITATIONS
19	Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase. <i>Biochemistry</i> , 2016, 55, 4574-4582.	1.2	12
20	Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3- <i>d</i>] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor $\hat{\pm}$ and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7856-7876.	2.9	30
21	Functional and mechanistic roles of the human proton-coupled folate transporter transmembrane domain 6â€™7 linker. <i>Biochemical Journal</i> , 2016, 473, 3545-3562.	1.7	5
22	Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3- <i>d</i>]Pyrimidine Thienoyl Antifolates. <i>Molecular Pharmacology</i> , 2016, 89, 425-434.	1.0	22
23	Structural determinants of human proton-coupled folate transporter oligomerization: role of CXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6. <i>Biochemical Journal</i> , 2015, 469, 33-44.	1.7	13
24	Novel 5-Substituted Pyrrolo[2,3- <i>d</i>]pyrimidines as Dual Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase and as Potential Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1479-1493.	2.9	22
25	6-Substituted Pyrrolo[2,3- <i>d</i>]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor $\hat{\pm}$ and the Proton-Coupled Folate Transporter in Human Tumors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6938-6959.	2.9	34
26	Substituted Cysteine Accessibility Reveals a Novel Transmembrane 2â€™3 Reentrant Loop and Functional Role for Transmembrane Domain 2 in the Human Proton-coupled Folate Transporter. <i>Journal of Biological Chemistry</i> , 2014, 289, 25287-25295.	1.6	16
27	Post-transcriptional regulation of the human reduced folate carrier as a novel adaptive mechanism in response to folate excess or deficiency. <i>Bioscience Reports</i> , 2014, 34, .	1.1	8
28	Biology of the Major Facilitative Folate Transporters SLC19A1 and SLC46A1. <i>Current Topics in Membranes</i> , 2014, 73, 175-204.	0.5	104
29	The Major Facilitative Folate Transporters Solute Carrier 19A1 and Solute Carrier 46A1: Biology and Role in Antifolate Chemotherapy of Cancer. <i>Drug Metabolism and Disposition</i> , 2014, 42, 632-649.	1.7	74
30	Structureâ€™Activity Profiles of Novel 6-Substituted Pyrrolo[2,3- <i>d</i>]pyrimidine Thienoyl Antifolates with Modified Amino Acids for Cellular Uptake by Folate Receptors $\hat{\pm}$ and $\hat{2}$ and the Proton-Coupled Folate Transporter. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8152-8166.	2.9	23
31	Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3- <i>d</i>]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 999-1011.	1.1	23
32	Discovery of 5-Substituted Pyrrolo[2,3- <i>d</i>]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 10016-10032.	2.9	33
33	Tumor-Targeting with Novel Non-Benzoyl 6-Substituted Straight Chain Pyrrolo[2,3- <i>d</i>]pyrimidine Antifolates via Cellular Uptake by Folate Receptor $\hat{\pm}$ and Inhibition of de Novo Purine Nucleotide Biosynthesis. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8684-8695.	2.9	24
34	The human proton-coupled folate transporter. <i>Cancer Biology and Therapy</i> , 2012, 13, 1355-1373.	1.5	135
35	Identification and Functional Impact of Homo-oligomers of the Human Proton-coupled Folate Transporter. <i>Journal of Biological Chemistry</i> , 2012, 287, 4982-4995.	1.6	34
36	Functional Loss of the Reduced Folate Carrier Enhances the Antitumor Activities of Novel Antifolates with Selective Uptake by the Proton-Coupled Folate Transporter. <i>Molecular Pharmacology</i> , 2012, 82, 591-600.	1.0	27

#	ARTICLE	IF	CITATIONS
37	Synthesis and Biological Activity of 6-Substituted Pyrrolo[2,3- <i>d</i>]pyrimidine Thienoyl Regioisomers as Inhibitors of de Novo Purine Biosynthesis with Selectivity for Cellular Uptake by High Affinity Folate Receptors and the Proton-Coupled Folate Transporter over the Reduced Folate Carrier. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1758-1770.	2.9	45
38	Synthesis, Biological, and Antitumor Activity of a Highly Potent 6-Substituted Pyrrolo[2,3- <i>d</i>]pyrimidine Thienoyl Antifolate Inhibitor with Proton-Coupled Folate Transporter and Folate Receptor Selectivity over the Reduced Folate Carrier That Inhibits I ² -Glycinamide Ribonucleotide Formyltransferase. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7150-7164.	2.9	62
39	Therapeutic Targeting of a Novel 6-Substituted Pyrrolo [2,3- <i>d</i>]pyrimidine Thienoyl Antifolate to Human Solid Tumors Based on Selective Uptake by the Proton-Coupled Folate Transporter. <i>Molecular Pharmacology</i> , 2011, 80, 1096-1107.	1.0	59
40	Identification of the Minimal Functional Unit of the Homo-oligomeric Human Reduced Folate Carrier. <i>Journal of Biological Chemistry</i> , 2010, 285, 4732-4740.	1.6	12
41	Targeting the Proton-Coupled Folate Transporter for Selective Delivery of 6-Substituted Pyrrolo[2,3- <i>d</i>]Pyrimidine Antifolate Inhibitors of De Novo Purine Biosynthesis in the Chemotherapy of Solid Tumors. <i>Molecular Pharmacology</i> , 2010, 78, 577-587.	1.0	53
42	Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking. <i>Biochemical Journal</i> , 2010, 430, 265-274.	1.7	4
43	Synthesis and Antitumor Activity of a Novel Series of 6-Substituted Pyrrolo[2,3- <i>d</i>]pyrimidine Thienoyl Antifolate Inhibitors of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors and the Proton-Coupled Folate Transporter over the Reduced Folate Carrier for Cellular Entry. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1306-1318.	2.9	63
44	Oligomeric Structure of the Human Reduced Folate Carrier. <i>Journal of Biological Chemistry</i> , 2009, 284, 3285-3293.	1.6	24
45	Synthesis and Biological Activity of a Novel Series of 6-Substituted Thieno[2,3- <i>d</i>]pyrimidine Antifolate Inhibitors of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors over the Reduced Folate Carrier and Proton-Coupled Folate Transporter for Cellular Entry. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2940-2951.	2.9	74
46	Synthesis and Discovery of High Affinity Folate Receptor-Specific Glycinamide Ribonucleotide Formyltransferase Inhibitors with Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5052-5063.	2.9	70
47	Role of Lysine 411 in Substrate Carboxyl Group Binding to the Human Reduced Folate Carrier, as Determined by Site-Directed Mutagenesis and Affinity Inhibition. <i>Molecular Pharmacology</i> , 2008, 73, 1274-1281.	1.0	16
48	Chapter 5 Structure and Function of the Reduced Folate Carrier. <i>Vitamins and Hormones</i> , 2008, 79, 145-184.	0.7	72
49	Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 111-128.	2.7	233
50	Transmembrane Domains 4, 5, 7, 8, and 10 of the Human Reduced Folate Carrier Are Important Structural or Functional Components of the Transmembrane Channel for Folate Substrates. <i>Journal of Biological Chemistry</i> , 2006, 281, 33588-33596.	1.6	26
51	Localization of a Substrate Binding Domain of the Human Reduced Folate Carrier to Transmembrane Domain 11 by Radioaffinity Labeling and Cysteine-substituted Accessibility Methods. <i>Journal of Biological Chemistry</i> , 2005, 280, 36206-36213.	1.6	31
52	The Metal Specificity and Selectivity of ZntA from <i>Escherichia coli</i> Using the Acylphosphate Intermediate. <i>Journal of Biological Chemistry</i> , 2003, 278, 28455-28461.	1.6	55